Clinical Trial Search

Primary: Average Pain Intensity Numerical Rating Scale (PI-NRS) Score - From 0 to 4 Hours Post-dose — 2.08; 2.73; 1.95; 2.04 Units on a scale

Primary: Average Daily Use of Cooling for Erythromelalgia-Related Pain in Treatment Period 2 — 0.24; 2.4 cooling uses/day

Primary: Carbamazepine Affects Pain in Patients With S241T NaV1.7 IEM Mutation — 3015; 136; 6360; 915 minutes

Primary: Erythema Multiforme Flares on Medication — 1.7 Number of flares

Primary: Change From Baseline in Average Daily Sunlight Exposure Time (Minutes) to First Prodromal Symptom (Burning, Tingling, Itching, or Stinging) Associated With Sunlight…

Primary: Change From Baseline in Average Daily Time (Minutes) to First Prodromal Symptom Associated With Sunlight Exposure Between Hour Post Sunrise and 1 Hour Pre-Sunset at Week…

Primary: Gastric Emptying Time — 105; 180 minutes — p=0.036

Primary: Number of Participants With a Decrease in Cramp Duration — 2; 0 participants

Primary: Change in Pain Numerical Rating Scale (NRS) — 43.75 units on a scale

Primary: Proportion of Subjects With Composite Success — 60; 58; 23 Participants

Primary: Responder — 16.7 percentage of responders

Primary: Percentage of Participants Who Are Very Satisfied/Satisfied/Somewhat Satisfied With the Overall Study Treatment — 69.6; 40.4 Percentage of participants — p== 0.0065

Primary: Response to Drug Based on Platelet Count at the End of Therapy — 91.6 percentage of participants

Primary: Long Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea. — -1.5; -1.4; -1.5; -1.7 scores on a scale

Primary: Improvement of the Inflammatory Lesions (Papules, Pustules, Nodules), Erythema, and Telangiectasia of Rosacea as Assessed by the Investigator's Global Assessment (IGA)…

Primary: Frequency of Vasospastic Attacks — 2.4; 2.0 attacks per day

Primary: Change in Erythrocyte Protoporphyrin Levels — 2314.6; 2240.4 µg/dL

Primary: The Hospital Anxiety and Depression Scale (HADS) — 4.6; 1.9 score on a scale

Primary: Number of Participants With a 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS) — 24; 9 participants

Primary: Percentage of Patients Who Have at Least a 50% Reduction (i.e., Success) in at Least 1 of the First 12 Chemotherapy Induced Peripheral Neuropathy (CIPN) Measurement…

Primary: Change From Baseline to Week 4 in the Weekly Average of the Daily Pain Score as Derived From the Subject's Responses on the Pain Intensity Numerical Rating Scale…

Primary: Change in International Restless Legs Syndrome Rating Scale (IRLS) — 19.5 score on a scale — p=0.0396

Primary: Change in Peak Oxygen Uptake (Peak VO2) Between the First and Second iCPET — 13.3; -40.3; 111.8 mL/min — p=0.043

Primary: Primary: Percentage of Treatment Success on Day 7 — 9.95; 10.36; 0 percentage of participants — p=<0.0001

Primary: Change From Baseline in Mean Raynaud's Condition Score (RCS) at Week 4 — 3.04; 2.90; 2.98; 3.14 units on a scale — p=0.6513

Primary: Duration of Direct Sunlight Exposure Between 10:00 and 18:00 Hours on Days When no Pain Was Experienced (Pain Score of 0). — 69.4; 40.8 hours

Primary: Composite Success — 36; 13; 36; 13 participants — p=<0.001

Primary: Change in Average Pain Scores From Baseline to Week 15/End of Treatment (EOT) — -2.22; -1.73; -1.30; -1.85 Scores on a Scale

Primary: Heart Rate Variability (Time Domain) — 0.92; 0.83 msec/msec — p=0.77

Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84